- Home
- ZSTK vs LSTA Comparison
ZSTK vs LSTA Comparison
Compare ZSTK & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZSTK | LSTA |
|---|---|---|
| Founded | 2019 | 1980 |
| Country | Canada | United States |
| Employees | 76 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0M | 16.4M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ZSTK | LSTA |
|---|---|---|
| Price | $8.25 | $5.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 12.5K | ★ 52.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $15.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $6.31 | $1.81 |
| 52 Week High | $11.00 | $5.07 |
Technical Indicators
Market Signals| Indicator | ZSTK | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 70.54 |
| Support Level | $7.78 | $2.31 |
| Resistance Level | $9.60 | $5.07 |
| Average True Range (ATR) | 0.62 | 0.08 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 71.14 | 95.19 |
Price Performance
Historical ComparisonAbout ZSTK ZeroStack Corp. Common Stock
ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide pharmaceutical distribution business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.